Quick Take
Aprea Therapeutics (APRE) has filed to raise gross proceeds of up to $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing cancer therapeutics that reactivate mutant p53 tumor suppressor protein.
APRE is in Phase 3 trials for its lead candidate with an expected next potential major milestone in the second half of 2020.
I’ll provide an update when we learn more IPO details from management.
Company & Technology
Boston, Massachusetts-based Aprea was founded in 2003 with a focus on developing cancer therapeutics that